Advances in IBD Precision Medicine With Therapeutic Drug Monitoring

Download All
Gain expert insights on when to use therapeutic drug monitoring proactively to improve the efficacy of biologic therapy for IBD and reactively to guide decision-making following primary nonresponse or secondary loss of response to a biologic.
Marla Dubinsky, MD
Bruce E. Sands, MD, MS

ClinicalThought

Two experts offer practical considerations for monitoring antidrug antibodies in patients with inflammatory bowel disease receiving anti-TNF therapy.

Marla Dubinsky, MD Bruce E. Sands, MD, MS Released: February 16, 2022

Should you screen every patient with inflammatory bowel disease for HLA-DQA1*05? Here’s our take.

Marla Dubinsky, MD Bruce E. Sands, MD, MS Released: March 2, 2022
Provided by the American Gastroenterological Association, in collaboration with Clinical Care Options.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Takeda Pharmaceuticals U.S.A., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings